Eric Karas - 08 Nov 2022 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Reporting relationship: Chief Commercial Officer
Issuer ticker: SPRY
Reported as of: 08 Nov 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Nov 2022, 17:00:47 UTC
Next SEC filing: 05 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Kathleen Scott, Attorney-in-Fact

Key filing fact

Eric Karas filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 10 Nov 2022.

Key facts

This page summarizes Eric Karas's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Nov 2022, 17:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRY transaction Derivative

Stock option (right to buy)

Award

Transaction value
Shares: +614,588
Change %
Price
Shares after: 614,588
Date: 08 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 614,588
Exercise price: $1.50
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

Footnote F2

Received in exchange for a stock option to acquire 520,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") with the exercise price of $1.77 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.